Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Apply
Tagraxofusp, Azacitidine, Venetoclax
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step